Dolby Laboratories Reports First Quarter 2025 Financial Results

Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the first quarter of fiscal 2025. https://mma.prnewswire.com/media/2561044/Dolby_Logo.jpg “We are off to a strong start for FY25,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “In Q1, Dolby Atmos and Dolby Vision momentum continued across device categories. At CES, many of our device partners announced […]

CPC Launches Industry-First Product for Cell and Gene Therapy Sterile Processing

CPC (Colder Products Company), part of Dover(NYSE: DOV) and a leading manufacturer of connection technologies used in biopharmaceutical processing, today announced the launch of its new MicroCNX® Nano Series aseptic connectors, designed to significantly simplify cell and gene therapy (CGT) closed sterile processing. https://mma.prnewswire.com/media/717019/Dover_blue_Logo.jpg “Cell and gene therapy is advancing quickly, but the industry relies

Bank of America Announces Redemption of $1,500,000,000 2.015% Fixed/Floating Rate Senior Notes, Due February 2026

Bank of America Corporation announced today that it will redeem on February 13, 2025, all $1,500,000,000 principal amount outstanding of its 2.015% Fixed/Floating Rate Senior Notes, due February 2026 (CUSIP No. 06051GHY8) (the “Notes”), at a redemption price equal to 100% of the principal amount of the Notes, plus accrued and unpaid interest to, but

Starwood Property Trust Announces Tax Reporting Information

Starwood Property Trust, Inc. (NYSE: STWD) (“the Company”) today announced the tax treatment for the Company's distributions on its common stock (CUSIP: 85571B105) paid with respect to the calendar year ended December 31, 2024: Form 1099-DIV Reference: (Boxes 1a + 2a + 3) Box 1a Box 1b Box 2a Box 2b Box 2e Box 2f

Heritage Provides Update on Fourth Quarter 2024 Financial Results and Estimated First Quarter 2025 Catastrophe Losses

Heritage Insurance Holdings, Inc. (NYSE: HRTG) (“Heritage” or the “Company”), a super-regional property and casualty insurance holding company, today provided an update on the Company's fourth quarter 2024 financial results as well as an estimate of catastrophe loss from the Southern California wildfires expected to be incurred in the first quarter 2025. https://mma.prnewswire.com/media/346373/heritage_insurance_logo.jpg Fourth Quarter

Arthur J. Gallagher & Co. Increases Cash Dividend to $0.65 per Share

Arthur J. Gallagher & Co. (NYSE: AJG) announced that its Board of Directors declared a sixty-five cents ($0.65) per share quarterly cash dividend on the company's common stock, a $0.05 increase over the prior quarter's dividend. The dividend will be payable on March 21, 2025 to Stockholders of Record as of March 7, 2025. Arthur

OPENLANE to Announce Fourth Quarter and Full Year 2024 Earnings

OPENLANE, Inc. (NYSE: KAR), a leading operator of digital marketplaces for wholesale used vehicles, will release its fourth quarter and full year 2024 financial results after the market closes on Wednesday, Feb. 19, 2025. https://mma.prnewswire.com/media/2067855/OPENLANE_Logo.jpg OPENLANE will also host an earnings conference call and webcast following the release on Wednesday, Feb. 19, 2025, at 5:00

InspireSemi Announces Administrative Update Webinar for Shareholders

VANCOUVER, British Columbia and AUSTIN, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) — Inspire Semiconductor Holdings Inc. (“InspireSemi” or the “Company”), a chip design company that provides revolutionary high-performance, energy-efficient accelerated computing solutions for High Performance Computing (HPC), AI, graph analytics, and other compute-intensive workloads, is pleased to announce that it will provide an administrative update

Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering

(NasdaqGM:DMAAU), Fort Lauderdale, FL, Jan. 29, 2025 (GLOBE NEWSWIRE) — Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU), (the “Company“) today announced that it closed its initial public offering of 20,000,000 units at $10.00 per unit. The gross proceeds from the offering were $200 million before deducting underwriting discounts and estimated offering expenses. The units

Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

(NasdaqGM:CMRX), DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) — Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside

Scroll to Top